Browse the evidence

Trans-resveratrol improves insulin sensitivity in skeletal muscle cells by potentiating insulin-induced Akt activation via AMPK activation.

Resveratrol may make your body's insulin work better in muscle cells. This happens when you have insulin present, suggesting it might help manage blood sugar more effectively if you have some insulin production or are using insulin therapy, but this is only proven in cell cultures.

Higher serum levels of indolepropionic acid (IPA), a gut microbiota metabolite derived from dietary tryptophan, are associated with a lower incidence of type 2 diabetes and reduced low-grade inflammation in high-risk individuals.

While you cannot directly supplement IPA effectively based on this study, the findings suggest that a diet high in fiber supports gut bacteria that produce IPA. This metabolic pathway is linked to lower inflammation and a reduced risk of type 2 diabetes. Prioritize fiber-rich whole foods to support this natural protective mechanism.

ETC-1002 (ESP55016) reduces circulating proatherogenic lipoproteins, hepatic lipids, and body weight in hyperlipidemic hamsters and improves glycemic control in diet-induced obese mice through dual inhibition of ATP-citrate lyase and activation of AMP-activated protein kinase.

ETC-1002 is an investigational small molecule designed to treat dyslipidemia and metabolic syndrome. In animal models, it lowered LDL cholesterol, reduced body weight, and improved blood sugar control by simultaneously activating AMPK (energy sensor) and inhibiting ATP-citrate lyase (lipid synthesis enzyme). It is not currently available for general use.

Inhibiting adipogenesis (the differentiation of preadipocytes into mature adipocytes) via modulation of transcription factors (C/EBP, PPARγ) and signaling pathways (Wnt, AMPK) is a viable therapeutic strategy for preventing or treating obesity.

This paper does not provide a direct lifestyle protocol but identifies the biological target: stopping the creation of new fat cells. For a layperson, this implies that interventions aiming to reduce obesity should focus on mechanisms that inhibit fat cell differentiation, such as those found in certain natural products or drugs targeting PPARγ or AMPK pathways, rather than just calorie restriction alone.

Natural products and conventional medications (Statins, Fibrates, Niacin) can inhibit or modulate adipogenesis through specific molecular pathways, offering potential anti-obesity effects.

Current medications like Statins and Fibrates, and various natural products, affect fat cell biology. Statins decrease lipid accumulation and increase small adipocytes. Fibrates increase fatty acid oxidation. Niacin stimulates adipogenesis markers. These mechanisms suggest that existing drugs have off-target effects on fat biology that could be leveraged.

Elevated circulating branched-chain amino acid (BCAA) levels are strongly associated with insulin resistance and type 2 diabetes, potentially acting as mediators through mTORC1 activation and accumulation of toxic metabolites like acylcarnitines and ceramides.

If you have insulin resistance or type 2 diabetes, high levels of branched-chain amino acids (found in protein) in your blood are linked to worse metabolic health. While protein is essential, simply consuming more BCAAs may not help and could potentially worsen insulin resistance in susceptible individuals. Focus on overall metabolic health and consult a provider before high-dose BCAA supplementation.

Bariatric surgery, specifically Roux-en-Y gastric bypass, reduces BCAA levels and improves insulin sensitivity, an effect not seen with weight loss alone via gastric banding.

If you undergo Roux-en-Y gastric bypass, your BCAA levels are likely to drop, which helps improve insulin sensitivity. This benefit is specific to the type of surgery and not just weight loss.

Chronic dietary administration of menthol activates TRPM8 channels in brown adipose tissue, triggering a PKA-dependent upregulation of UCP1 that increases thermogenesis and prevents diet-induced obesity and glucose intolerance in mice.

This research suggests that chronic consumption of menthol (specifically 0.5% of diet in mice) can activate cold-sensing channels in fat tissue to burn calories and prevent obesity. While promising in mice, translating this to humans requires confirming that adult humans have sufficient TRPM8 expression in brown fat and that dietary menthol doses are safe and tolerable long-term. It is not a quick fix but a potential metabolic modulator.

Activation of the Constitutive Androstane Receptor (CAR) using the agonist TCPOBOP prevents and reverses obesity and improves insulin sensitivity in high-fat diet-induced and genetic mouse models of type 2 diabetes.

This research identifies the Constitutive Androstane Receptor (CAR) as a potential target for treating obesity and type 2 diabetes. While the specific drug used (TCPOBOP) is experimental, the findings suggest that activating CAR through approved drugs (like phenobarbital) or nutraceuticals might help manage metabolic health. Current evidence is limited to animal models, so human application requires further clinical validation.

Both aerobic and resistance training significantly increase plasma fibrinogen levels in middle-aged, android-obese men, which is a paradoxical increase in a known cardiovascular risk factor.

Be aware that short-term exercise training might temporarily increase fibrinogen, a blood clotting factor. This does not negate the benefits of exercise but suggests monitoring may be needed in high-risk individuals.

Thyroid hormone analogs (thyromimetics) targeting specific thyroid hormone receptors (TRs) have been proposed to treat obesity and metabolic diseases by increasing energy expenditure without the adverse systemic effects of supraphysiologic thyroid hormone doses.

Thyroid hormone supplementation is not a safe or approved treatment for obesity due to adverse side effects. Research into targeted thyroid hormone analogs (thyromimetics) is ongoing, but no such therapies have been approved by the FDA. Lifestyle interventions remain the standard of care.

Inhibition of the host enzyme indoleamine 2,3-dioxygenase 1 (IDO1) improves metabolic health by shifting tryptophan metabolism toward gut microbiota-derived indole metabolites, which restore intestinal barrier integrity and reduce systemic inflammation.

To support metabolic health, prioritize dietary patterns that foster a diverse gut microbiome capable of converting dietary tryptophan into protective indole metabolites. This involves consuming sufficient fiber and diverse plant sources. Emerging research suggests that inhibiting the host enzyme IDO1 (which is upregulated in obesity) allows the microbiota to produce more of these beneficial indoles, thereby improving insulin sensitivity and reducing inflammation. While direct IDO1 inhibitors are not yet standard care, supporting the microbiome's ability to perform this conversion is a key mechanistic target.

Acute resistance training increases plasma Interleukin-6 (IL-6) levels, which acts as an anti-inflammatory myokine when derived from muscle, promoting fat oxidation via AMPK activation and inhibiting pro-inflammatory cytokines like TNF-α.

Do not fear the rise in IL-6 after a resistance workout. When your muscles produce IL-6 during exercise, it acts as a beneficial signal that helps burn fat and improves insulin sensitivity, unlike the chronic IL-6 produced by fat tissue which contributes to inflammation.

Elevated serum levels of the pro-inflammatory cytokine IL-6 and the IL-6/IL-10 ratio are positively associated with the presence of sarcopenia in elderly individuals.

For older adults, high levels of systemic inflammation (specifically IL-6) are linked to muscle loss. While you cannot directly 'dose' IL-6, managing chronic inflammation through diet, exercise, and medical management of inflammatory conditions may help preserve muscle mass. The study highlights that inflammation is a key biological driver, not just a side effect.

Elevated levels of the anti-inflammatory cytokine IL-10 are also positively associated with sarcopenia in the elderly, potentially acting as a compensatory response to chronic inflammation.

High IL-10 levels in sarcopenia may indicate the body's attempt to fight inflammation. This suggests that simply boosting anti-inflammatory markers might not be enough if the underlying pro-inflammatory drive (IL-6) is too strong. Focus on reducing overall inflammatory load.

Dietary flavonoids reduce intestinal inflammation and improve barrier integrity in obesity-associated models by suppressing the TLR4/NF-κB signaling pathway and down-regulating pro-inflammatory enzymes like COX-2 and iNOS.

To leverage flavonoids for gut health and inflammation, prioritize foods rich in specific flavonoids (like citrus for naringenin, tea for catechins, or red wine for anthocyanidins) because they interact directly with gut bacteria and intestinal cells. The benefit comes from local gut effects and microbiota modulation rather than high systemic blood levels.

Administration of the highly proliferative probiotic strain Bifidobacterium animalis ssp. lactis GCL2505 (BlaG) ameliorates metabolic disorders, specifically improving glucose tolerance and reducing visceral fat accumulation, by modulating gut microbiota to elevate acetate levels and subsequently increasing glucagon-like peptide-1 (GLP-1) secretion.

If you are looking to use probiotics to support metabolic health, specifically glucose control and fat management, the specific strain matters significantly. This research suggests that Bifidobacterium animalis ssp. lactis GCL2505, taken daily at 1 billion CFU, may help improve glucose tolerance and reduce visceral fat in the context of a high-fat diet by increasing gut acetate and GLP-1. However, this was observed in mice, and human results may vary. It highlights that 'proliferative' strains might be more effective than non-proliferative ones for these specific outcomes.

Small molecule sirtuin activators, specifically polyphenols like resveratrol, extend lifespan in yeast by mimicking the effects of calorie restriction through the activation of Sir2.

While direct human lifespan extension is not yet proven, consuming plant-based polyphenols (like resveratrol found in grapes) may activate longevity pathways (sirtuins) that mimic the benefits of calorie restriction. This suggests that a diet rich in stressed plants (grapes, peanuts, medicinal herbs) could support cellular health and stress resistance.

Probiotic administration in early life, likely via the production of short-chain fatty acids (SCFAs) like butyrate, can restore gut microbiota balance and exert epigenetic effects (HDAC inhibition) that prevent chronic immune-mediated diseases.

If considering probiotics for an infant (especially after C-section or antibiotic use), consult a pediatrician. The goal is to support a healthy gut microbiota early in life, which may help program a robust immune system and reduce the risk of allergies via epigenetic mechanisms like butyrate production.

IL-22, produced by Th22 cells, has a beneficial effect on NAFLD by alleviating steatosis and reducing transaminase levels through STAT3-mediated mechanisms, although its role in obesity pathogenesis is complex and context-dependent.

IL-22 shows promise in reducing liver fat and inflammation in NAFLD models. While not a current standalone therapy, understanding its protective role highlights the potential of targeting specific cytokine pathways for liver health. Current management focuses on weight loss and metabolic control.

Obesity is associated with an increased risk of differentiated thyroid cancer (DTC), potentially mediated by higher TSH levels, insulin/IGF-1 pathways, and adipokines like leptin.

Obesity is linked to a higher risk of thyroid cancer. This may be due to higher TSH, insulin, and fat-derived hormones. Maintaining a healthy weight may help reduce this risk.

Caloric restriction extends lifespan and promotes longevity by inducing dramatic changes in mitochondrial protein acetylation, thereby enhancing mitochondrial adaptation to reduced caloric intake.

Caloric restriction is a proven method to extend lifespan in various species by altering how mitochondria function. This happens through changes in protein acetylation, which helps cells adapt to lower energy availability. While strict restriction is hard to maintain, the underlying mechanism suggests that managing energy intake to avoid overfeeding may support healthy aging processes.

Dietary fish oil (n-3 fatty acids) preserves hepatic insulin sensitivity in high-fat diet-fed wild-type mice by activating PPAR-α, which reduces hepatic diacylglycerol levels; this protective effect is abolished in PPAR-α null mice, demonstrating PPAR-α dependence.

Fish oil supplementation may help maintain liver sensitivity to insulin when consuming a high-fat diet, but this benefit relies on having functional PPAR-α. The mechanism involves reducing specific lipid signals (diacylglycerol) rather than just lowering total liver fat. For humans, this suggests fish oil is a supportive tool for metabolic health, particularly if you have high fat intake, but it is not a standalone cure for insulin resistance.

Aberrant protein posttranslational modifications (PTMs) are central drivers of metabolic diseases including diabetes, obesity, and atherosclerosis, and targeting these modifications offers a viable therapeutic strategy.

Metabolic diseases are driven by complex molecular switches (PTMs) that regulate how your body processes energy. While lifestyle changes are the first line of defense, pharmaceutical interventions targeting these specific molecular pathways (like kinase inhibitors) are increasingly available and effective for managing conditions like diabetes and fatty liver disease when lifestyle changes are insufficient.